Malin Corporation PLC Directorate Change (8074H)

TIDM0Y71

RNS Number : 8074H

Malin Corporation PLC

02 August 2019

Malin Corporation plc

Malin announces Board changes

Dublin-Ireland, 2 August 2019: Malin Corporation plc. (Euronext Growth Dublin:MLC) ("the Company"), a company investing in highly innovative life sciences companies, today announces that Ian Curley has retired as Chairman, and as a member of the Board. This is consistent with the announcement made noting Mr Curley's intention to retire from the Board and to step down as Chairman at the Company's Annual General Meeting on 9 May 2019.

The Board is pleased to announce that Liam Daniel, currently an Independent Non-Executive Director of the Board, will assume the position of Non-Executive Chairman of the Board with immediate effect. Liam brings over 25 years of pharmaceutical and biotech industry experience in both management and board roles. He has served on the board of a number of listed public companies and is currently a director of Horizon Therapeutics, plc and of the Institute of Directors in Ireland where he served as President of that organisation from 2013 to 2015.

Mr Daniel said, "I look forward to leading the Board of Malin as the Company continues on its focused path of delivering shareholder value from its assets. Malin has significant stakes in some of the highest quality clinical-stage healthcare companies including Poseida, Immunocore and Kymab. We are grateful to Ian for his dedication and commitment in leading the Malin Board over the last year and wish him well in the future."

The Company has initiated a process, with the help of a leading global search firm, to identify and recruit a new Independent Non-Executive Director to augment the existing Board.

ENDS

About Malin Corporation plc

Malin (Euronext Growth Dublin:MLC) is a company investing in and supporting highly innovative life sciences companies developing exceptional science and technology to deliver transformative outcomes for patients and create significant value for shareholders. Its purpose is to create shareholder value through the application of long-term capital and strategic support to its investee companies to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on the Euronext Growth Dublin. For more information visit www.malinplc.com

For further information please contact:

Malin

Jessica Bergin, Investor Relations & External Reporting

Tel: +353 (0)1 901 5700

investorrelations@malinplc.com

Davy Corporate Finance (Euronext Growth Adviser & Joint Broker)

Brian Garrahy / Daragh O'Reilly

Tel: +353 1 679 6363

Liberum (Joint Broker)

Bidhi Bhoma / Euan Brown

Tel: +44 (0) 20 3100 2000

Consilium Strategic Communications

Mary-Jane Elliott / Chris Welsh

Tel: +44 (0)20 3709 5700

malin@consilium-comms.com

Powerscourt (Irish media enquiries)

Jack Hickey

Tel: +353 83 448 8339

malin@powerscourt-group.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BOACKBDQPBKDAFK

(END) Dow Jones Newswires

August 02, 2019 12:00 ET (16:00 GMT)

Malin (LSE:0Y71)
Historical Stock Chart
From Jun 2024 to Jul 2024